Arch Biopartners Announces St. Michael’s Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide
View original at globenewswire.comArch Biopartners Announces St. Michael’s Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide TORONTO, March 20, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
No adverse events or serious adverse events have been assessed as related to cilastatin in the PONTiAK trial and new patient recruitment is ongoing at both active clinical sites
60% confidenceClinical studies report that up to 30% of patients undergoing on-pump cardiac surgery develop CS-AKI, a condition that increases the risk of serious complications, longer hospital stays, and increased mortality
60% confidenceArch scientists and their collaborators have reported that LSALT reduced IRI to the kidneys in preclinical models
60% confidenceKidney and related conditions affect more than 800 million people worldwide
60% confidencePublished studies have reported that medications are associated with AKI in 14%–26% of adults in prospective cohort studies, and that AKI can occur in up to 25% of patients exposed to nephrotoxic pharmaceuticals
60% confidencePatients treated with LSALT peptide showed reductions in a range of inflammation-related biomarkers, including a reported statistically significant decrease in CXCL10, a protein linked to inflammation in the lungs and kidneys
60% confidenceThere are currently no approved pharmacologic therapies indicated to prevent acute kidney injury of the type commonly experienced by on-pump cardiac surgery patients
60% confidenceInvestigators and medical monitors have not assessed any adverse events or serious adverse events as related to LSALT peptide, and there have been no SUSARs reported in the trial
60% confidenceExpanding to selected U.S. sites is intended to broaden clinical awareness of LSALT peptide among cardiac surgery and kidney care specialists, while also supporting the acceleration of patient recruitment
60% confidenceThe Company's blinded review of trial data indicates that AKI has been consistently observed using the protocol-defined criteria, supporting the trial's study design and defined endpoints
60% confidence